ALNY: Symmetrical Triangle detected on 25 Sep 2026

Alnylam is forming a symmetrical triangle as the stock consolidates with tight structure. At $249.59, price sits near the midpoint of the consolidation zone between support at $242.31 and resistance at $250.54. The pattern quality metrics show moderate strength: structure score of 11/15 indicates orderly price action, breakout score of 12/13 suggests directional readiness, but volume score of 7/12 reveals below-average participation at 0.58 relative volume (920K vs. 1.59M average). The 56.81% win probability indicates slight edge favoring upside resolution. A breakout above resistance targets $262.17 conservatively, representing 5.0% measured move.

ALNY reported Q2 2026 revenues of $1.172 billion (74% YoY growth), driven by TTR franchise totaling $1.030 billion (89% YoY growth). The company lowered TTR guidance from $4.4-4.7B to $4.2-4.5B for full-year 2026, reflecting normalization in the ATTR-CM market after initial launch momentum. Regeneron announced FDA and EMA accepted regulatory applications for cemdisiran in generalized myasthenia gravis, with FDA Priority Review targeting November 2026. ALNY initiated Phase 1 for ALN-2232, its first adipose-targeted RNAi therapeutic for obesity and weight management. The stock traded down 14.87% over three months despite strong revenue growth, reflecting market disappointment over revised TTR guidance and normalization concerns that now create consolidation opportunity.

A successful breakout above $250.54 resistance would signal upside resolution of the symmetrical triangle. Volume confirmation is needed given current participation at 58% of average volume. The measured move target of $262.17 represents approximately 5.0% upside from breakout level, achievable within 2-4 weeks historically for this pattern type with 56.81% win probability supporting technical strength. Invalidation occurs decisively on close below support at $242.31, which would breach the consolidation floor and suggest downside reversal. RSI at 51.92 provides neutral initialization for directional move without overbought constraints.

Guidance reduction in July signals lingering execution concerns in the core ATTR-CM launch despite billion-dollar quarterly revenues. The stock remains 49.63% below 52-week highs, indicating structural weakness even as recent data progress accumulates. Volume participation is critically weak at 58% of average—breakout may lack conviction if institutional buying fails to materialize. Pipeline timeline risk: multiple clinical readouts expected H2 2026 could accelerate or disappoint, triggering rapid re-rating. Cemdisiran regulatory decision in November (per Regeneron) creates binary near-term event risk within consolidation window. Negative beta of -0.3 may provide downside hedge if broader biotech sector weakens, but limits participation in bullish market regime. Volatility at 3.78% ATR offers limited risk buffer for technical stop placement below $242.31.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.